Ingredient or product comparison
GHK-Cu vs Minoxidil vs Finasteride: Hair Growth Research Comparison
Researchers evaluating hair loss interventions need to understand how GHK-Cu stacks up against established therapies. Not just in efficacy but in mechanism, administration burden, and adverse event profile. GHK-Cu (topical) VEGF upregulation, TGF-β1 inhibition
This source-based comparison does not add ratings or recommend a winner.
- Researchers evaluating hair loss interventions need to understand how GHK-Cu stacks up against established therapies. Not just in efficacy but in mechanism, administration burden, and adverse event profile.
- GHK-Cu (topical)
- VEGF upregulation, TGF-β1 inhibition, keratinocyte proliferation via integrin receptor binding
- 1.5–3mM solution twice daily
- 18–28% increase from baseline
- <5% (mild scalp dryness)
- Best for frontal/temporal thinning in patients intolerant to minoxidil; lacks systemic DHT suppression so limited efficacy in advanced androgenetic alopecia
- Minoxidil 5% (topical)
- Vasodilation via ATP-sensitive potassium channel opening; increases follicular blood flow
- Twice daily application
- 25–35% increase from baseline (vertex), 10–18% (frontal)
- 15–22% (scalp irritation, pruritus, contact dermatitis)
- Gold standard for topical therapy; superior vertex response but less effective at hairline; requires continuous use or rapid shedding occurs
- Finasteride 1mg (oral)
- Type II 5-alpha-reductase inhibition; reduces scalp DHT by ~70%
- 1mg daily oral tablet
- 40–55% increase in hair count at 48 weeks
- 2–4% (sexual dysfunction, depression, gynecomastia)
- Most effective single-agent therapy for androgenetic alopecia in men; systemic mechanism addresses root hormonal cause; not suitable for women of childbearing age
- Dutasteride 0.5mg (oral)
- Dual Type I and II 5-alpha-reductase inhibition; reduces scalp DHT by ~90%
- 0.5mg daily oral capsule
- 50–65% increase in hair count at 48 weeks
- 4–7% (sexual dysfunction, reduced libido)
- Stronger DHT suppression than finasteride; used off-label for hair loss; longer half-life (4–5 weeks) means extended washout if discontinued
- GHK-Cu occupies a distinct position: it's a non-hormonal, non-vasodilator option with follicle-level regenerative effects. It won't replace finasteride for patients whose hair loss is driven primarily by DHT, and it may not match minoxidil's vertex response in absolute hair count. What it offers is frontal efficacy, minimal side effects, and a mechanism that could theoretically complement oral or topical androgens rather than duplicate them.
- Combination therapy is the next frontier. A 2025 pilot study published in Clinical, Cosmetic and Investigational Dermatology tested GHK-Cu plus minoxidil versus minoxidil alone in 48 participants. The combination group achieved 41% improvement in hair density at 24 weeks versus 29% for minoxidil monotherapy. The hypothesis: minoxidil increases blood flow, GHK-Cu stimulates follicular proliferation and matrix remodeling. Two complementary mechanisms that address different rate-limiting factors in hair growth.
- For research applications, choosing between these agents depends on study objectives. If the goal is to model hormonal pathways in alopecia, finasteride or dutasteride is appropriate. If the research question involves angiogenesis or wound healing parallels in follicle regeneration, GHK-Cu is the better fit. And if the protocol needs to avoid systemic effects entirely. For example, in female participants or in combination with other oral medications. Topical GHK-Cu avoids the drug-drug interaction concerns that oral 5-alpha-reductase inhibitors introduce.